Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-18T10:33:30.598Z Has data issue: false hasContentIssue false

P03-347 Transitioning Onto OROS MPH is Associated with Improved Functioning and Quality of Life in Children and Adolescents with ADHD

Published online by Cambridge University Press:  17 April 2020

A. Kordon
Affiliation:
Department of Psychiatry, University of Lübeck, Lübeck, Germany
W. Hultzsch
Affiliation:
Child and Adolescent Psychiatry, Private Practice, Munich, Germany
F. Mattejat
Affiliation:
Dept. of Child and Adolescent Psychiatry, University of Marburg, Marburg, Germany
S. Dichter
Affiliation:
Janssen Cilag GmbH, Neuss, Germany
B. Schaeuble
Affiliation:
EMEA Medical Affairs, Janssen Cilag GmbH, Neuss, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

To explore functionality and quality of life outcomes in children and adolescents with ADHD transitioning from IR MPH, ER MPH or ATX onto OROS MPH.

Methods

Pooled analyses of two similar 12 week open label, flexibly dosed studies including children (6-18 yrs) diagnosed with ADHD (ICD-10) transitioning from shorter acting stimulants or Atomoxetine onto OROS MPH. Connor's parents rating scale, children's global assessment scale and quality of life (ILC, LQ-0-28) were applied.

Results

822 patients (84.9% boys; median age 10 yrs) were analyzed. 81% of patients concluded the study. Starting and final dose was based on physician's judgment. Median dose at baseline and endpoint was 36mg/day. On average, C-GAS ratings improved by 12 points (p< 0.001). The percentage of children showing “variable functioning with sporadic difficulties” at baseline or worse decreased from 57,2% to 43,3% at endpoint. 61% of patients improved by at least 30% on CPRS. The percentage of children meeting educational demands at school at least “rather good” increased from 26,6% to 47,4% at endpoint. Results were similar for “social interaction with other children”, “emotional status”, “occupying with him or herself”. Burden of disease (patients or care givers) decreased (p< 0.001). Improved C-GAS and LQ 0-28 correlated with decreased CPRS. Treatment emergent AEs occurred in 35.6%. AEs ≥ 4%: insomnia (8%), muscle twitches (5%) and anorexia (4%).

Conclusion

Transitioning onto OROS MPH was associated with clinically relevant improvements in daily functioning, aspects of quality of life and decreased burden of disease in patients and their cares.

Type
Psychopharmacological treatment and biological therapies
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.